Pharma-Biotech Sector Hopes Merger & Acquisition Buying Spree Can Cure Financial Pains
SUGAR LAND--June 4, 2008 Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- In addition to developing drugs for the marketplace the old fashioned way, with benefit of labs and scientists, pharma-biotech companies are increasingly turning to cash to pay for mergers and acquisitions that will hopefully fill their pipelines. Companies featured: AstraZeneca (NYSE:AZN), Schering-Plough (NYSE:SGP), Mylan Laboratories (NYSE:MYL), Merck & Company (NYSE:MRK), Emergent BioSolutions Inc. (NYSE:EBS), Bristol-Myers Squibb Company (NYSE:BMY), Kosan Biosciences Inc. (NASDAQ:KOSN)
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here